Hello all, I recorded the interview above with Rachel Pether from SALT (the alternative investment conference/forum founded by Anthony Scaramucci).
MICAHEL FRAZIS | 4/6/2021
Portfolio Manager, Managing Partner
This Weeks Guest.
Robert Stretch, MD
New Episodes Weekly
Live Every Thursday @ 9am
Dr. Robert Stretch is a specialist in Pulmonary, Critical Care & Sleep Medicine.
After graduating from Yale School of Medicine in 2014, he completed subspecialty training at BIDMC, a Harvard teaching hospital in Boston, and UCLA Medical Center in Los Angeles.
0:05 – Introducing Robert Stretch
0:25 – Robert’s journey studying medicine in the US
3:40 – Findings when working on the MIMIC (Medical Information Mart for Intensive Care) database at MIT University
9:31 – Robert’s move into sleep apnoea
12:23 – What is sleep apnoea?
16:47 – What are the main risk factors for developing sleep apnoea?
17:26 – What is the current standard of care for sleep apnoea?
18:26 – Working in US ICU’s remotely from Sydney
23:11 – The need for remote ICU doctors
26:00 – Robert’s experience treating Covid patients in ICU
31:58 – Why are older people more vulnerable to Covid-19?
33:19 – Assessment of the Australian government’s Covid-19 support and vaccine distribution
40:30 – Outlook on Australian biotech companies
46:52 – What is RNAi technology?
52:40 – Pricing of vaccines and antibiotics globally
59:04 – Link between Alzheimer’s and Gingivitis
Signup for Frazis Insights
Get monthly shareouts from the Frazis team, keep up to date on perspectives, interviews, features, spaces and more.
You might also like…
Michael Frazis describes his investment company’s strategy that involves a 30-40 year view, not panicking and diverting the approach during dips and rallies.
Michael Frazis attempts to understand the FDA’s decision to approve Biogen’s aducanumab for Alzheimer’s and the possible ramifications.